Immune-related adverse events (irAEs) predict therapeutic efficacy of an anti-PD-1 antibody in cancer patients von Rogado, J., Romero Laorden, N., Sanchez Torres, J.M., Ballesteros Garcia, A.I., Pacheco-Barcia, V.E., Arranz, R., Mondéjar Solís, R., Gullón, P., Lorenzo, A., Colomer Bosch, R.

Volltext

PRIME Study": Searching for immune biomarkers in advanced castration resistant prostate cancer (CRPC) patients treated with standard therapy von Romero-Laorden, N., Zapatero, A., San Jose, L., Lozano Mejorada, R., Pacheco, M.I., Rivera, L., Hernandez, I., Aragon, I., González, T., Colomer Bosch, R.

Volltext

Safety and outcomes of self-expandable metal stents (SEMS) versus emergency surgery for acute colonic obstruction in metastatic colon cancer patients treated with bevacizumab (BV) von Pacheco-Barcia, V.E., Mondéjar Solís, R., Martínez-Sáez, O., Longo, F., Bermejo, E., Moreno, J.A., Marin, C., Correa, A., Maqueda, R., Rogado, J., García de Paredes, A., Rodriguez de Santiago, E., Pachón Olmos, V., Ferreiro Monteagudo, R., Rodriguez Garrote, M., Carrato Mena, A., Donnay, O., Martin Perez, E., Santander, C., Colomer Bosch, R.

Volltext

Addition of durvalumab (Dur) upon progression to bevacizumab (Bev) maintenance in advanced HER2-negative (HERNEG) breast cancer (BC): Safety, efficacy and biomarkers von Quintela-Fandino, M., Manso Sànchez, L.M., Holgado Martín, E., Moreno, M.C., Morales Murillo, S., Bermejo De Las Heras, B., Malon Gimenez, D., Colomer Bosch, R., Gonzalez Cortijo, L., Hornedo, J., Mouron, S., Muñoz, M., Escudero, S., Blanco, R., Mañes, S.

Volltext

1469P The role of the CXCL12/CXCR4 pathway in the immunotherapy of non-small cell lung cancer von Rogado, J., Pozo, F., Troule, K., Pacheco, M., Adrados, M., Sanchez Torres, J.M., Al-Shahrour, F., Alfranca, A., Romero Laorden, N., Colomer Bosch, R.

Volltext

213P Constructing a high-definition patient-digital twin (PDT) in treatment-naïve women with advanced cancer von Garma, L.D., Jimenez, D., Baz, D. Vicente, Vera, R., Bermejo, B., Gonzalez, S., Simon, S. Pernas, Torres, J.M. Sanchez, Nasarra-Lopez, B., Grimalt, B. Fullana, Rodriguez, M., Cruz, S. de la, Paz, L., Sauras, M., Villalba, M.A., Artes-Rodriguez, A., Bosch, R. Colomer, Quintela-Fandino, M.

Volltext

1756P Cancer patients infected with COVID-19 at La Princesa Hospital: Real-world data study von Toquero Diez, P., Vera Cea, B., Garrido Garcia, A., Méndez Carrascosa, E.R., Bañón Torres, D., Colomer Bosch, R., Romero Laorden, N., Hernández, B.

Volltext

1621P Emotional distress in cancer patients during the first wave of the COVID-19 pandemic in Madrid von Diez, P. Toquero, Fernández, C. Blanco, Cea, B. Vera, Carrascosa, E. Méndez, García, A. Garrido, Candil, O. Donnay, García, A.I. Ballesteros, Sánchez-Torres, J.M., Rojo, P. Costas, Solís, R. Mondéjar, Hernandez, B., Martí, M.D.P. López, Bosch, R. Colomer, Laorden, N. Romero

Volltext

561P - Oncological outcome and safety of bevacizumab (BV) therapy in patients with occlusive colon cancer and self-expandable metal stents (SEMS) von Pacheco-Barcia, V.E., Mondejar, R., Martinez-Saez, O., Munoz, F Longo, Monteagudo, J A Moreno, Rogado, J., Donnay, O., Santander, C., Mena, A Carrato, Bosch, R Colomer

Volltext

A systemic inflammation response index (SIRI) correlates with survival and could be a predictive factor for mFOLFIRINOX in metastatic pancreatic cancer (PC) von Pacheco-Barcia, V.E., Mondejar, R., France, T., Asselah, J., Donnay, O., Zogopoulos, G., Bouganim, N., Guo, K., Martin, E., Alcindor, T., Colomer Bosch, R.

Volltext

561POncological outcome and safety of bevacizumab (BV) therapy in patients with occlusive colon cancer and self-expandable metal stents (SEMS) von Pacheco-Barcia, V E, Mondejar, R, Martinez-Saez, O, Munoz, F Longo, Monteagudo, J A Moreno, Rogado, J, Donnay, O, Santander, C, Mena, A Carrato, Bosch, R Colomer

Volltext

Oncological outcome and safety of bevacizumab (BV) therapy in patients with occlusive colon cancer and self-expandable metal stents (SEMS) von Pacheco-Barcia, V.E., Mondejar, R., Martinez-Saez, O., Munoz, F Longo, Monteagudo, J A Moreno, Rogado, J., Donnay, O., Santander, C., Mena, A Carrato, Bosch, R Colomer

Volltext

143P - A systemic inflammation response index (SIRI) correlates with survival and could be a predictive factor for mFOLFIRINOX in metastatic pancreatic cancer (PC) von Pacheco-Barcia, V.E., Mondejar, R., France, T., Asselah, J., Donnay, O., Zogopoulos, G., Bouganim, N., Guo, K., Martin, E., Alcindor, T., Colomer Bosch, R.

Volltext

143PA systemic inflammation response index (SIRI) correlates with survival and could be a predictive factor for mFOLFIRINOX in metastatic pancreatic cancer (PC) von Pacheco-Barcia, V E, Mondejar, R, France, T, Asselah, J, Donnay, O, Zogopoulos, G, Bouganim, N, Guo, K, Martin, E, Alcindor, T, Colomer Bosch, R

Volltext

153P The Systemic Inflammation Response Index (SIRI) is a prognostic factor that correlates with tumor burden in advanced pancreatic cancer von Pacheco-Barcia, V.E., France, T., Asselah, J., Mondejar, R., Zogopoulos, G., Serrano, R., Donnay, O., Rogado, J., Del Campo, L., Martinez, E., Martin, E., Arlanzon, C., Ochoa, P., Guo, K., Barrena, G., Colomer Bosch, R.

Volltext

504P Primary tumour location impacts oncological outcome of patients with resected colorectal liver metastases von Pacheco-Barcia, V.E., Cea, B. Vera, Garrido, A., Donnay, O., Diez, P. Toquero, Mondejar, R., Serrano, R., Martin, E., Laorden, N. Romero, di Martino, M., Del Campo, L., Bosch, R. Colomer

Volltext

57TiP"PRIME Study": Searching for immune biomarkers in advanced castration resistant prostate cancer (CRPC) patients treated with standard therapy von Romero-Laorden, N, Zapatero, A, San Jose, L, Lozano Mejorada, R, Pacheco, M I, Rivera, L, Hernandez, I, Aragon, I, González, T, Colomer Bosch, R

Volltext

1227PImmune-related adverse events (irAEs) predict therapeutic efficacy of an anti-PD-1 antibody in cancer patients von Rogado, J, Romero Laorden, N, Sanchez Torres, J M, Ballesteros Garcia, A I, Pacheco-Barcia, V E, Arranz, R, Mondéjar Solís, R, Gullón, P, Lorenzo, A, Colomer Bosch, R

Volltext

Excess weight and efficacy of anti-PD-1 antibodies in advanced cancer patients von Rogado, J., Laorden, N Romero, Torres, J M Sanchez, Ramos-Levi, A., Pacheco-Barcia, V.E., Garcia, A I Ballesteros, Arranz, R., Lorenzo, A., Gullon, P., Garrido, A., Serra, J.M., Donnay, O., Adrados, M., Costas, P., Aspa, J., Alfranca, A., Mondejar, R., Bosch, R Colomer

Volltext

1287PExcess weight and efficacy of anti-PD-1 antibodies in advanced cancer patients von Rogado, J, Laorden, N Romero, Torres, J M Sanchez, Ramos-Levi, A, Pacheco-Barcia, V E, Garcia, A I Ballesteros, Arranz, R, Lorenzo, A, Gullon, P, Garrido, A, Serra, J M, Donnay, O, Adrados, M, Costas, P, Aspa, J, Alfranca, A, Mondejar, R, Bosch, R Colomer

Volltext